We are advised by Deko Cocktails that journalists and other readers should disregard the news release, Deko Cocktails Ignites Statewide Expansion with Southern Glazer's Wine & Spirits, issued 27-Aug-2025 over PR Newswire. SOURCE Deko Cocktails https://rt.newswire.ca/rt.gif?NewsItemId=PH59229&Transmission_Id=202509020708PR_NEWS_USPR_____PH59229A&DateId=20250902
Cinnamon and Garlic Bread Bites join Domino's $6.99 Mix & Match Deal Domino'sPizza Inc. (Nasdaq: DPZ)is bringing more oven-baked deliciousness to its customers by launching two new Bread Bite flavors: Cinnamon and Garlic. https://mma.prnewswire.com/media/2760516/Dominos_Pizza_New_Bread_Bites.jpg Domino's oven-baked Bread Bites are handmade from fresh buttery-tasting dough. Cinnamon and Garlic Bread Bites join Domino's Parmesan Bread Bites, adding
CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM), which will be held September 2-6, 2025 in Kyoto, Japan, at the Kyoto International Conference Center.
RiskSpan, a leading provider of data analytics solutions for the structured finance industry, today announced the release of Agentic AI for MBS Data, an AI-powered MBS analyst that delivers instant, sourced, and context-rich analysis in plain English – no coding required. https://mma.prnewswire.com/media/2757408/RiskSpan_Logo_v1_Logo.jpg Solving the MBS Data BottleneckWhile Agency MBS loan data is readily available, meaningful
Stempeck to lead and expand Brennan's Capital Markets team, strengthening financing strategies for national acquisitions and developments Brennan Investment Group (“Brennan”), a private real estate investment firm that acquires, develops, and operates industrial facilities throughout the United States, is pleased to announce the promotion of CJ Stempeck to Senior Vice President, Capital Markets from his
(NASDAQ:ZBIO),(NASDAQ:RPRX), – Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease – – Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease – WALTHAM, Mass. and New York, Sept. 02, 2025
(Other OTC:KBLB),(OTC US:KBLB), ANN ARBOR, Mich., Sept. 02, 2025 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that Dr. Nirmal Kumar, the Company's lead sericulture expert, has arrived in Southeast Asia to support the production team at its recently established second
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million GlobeNewswire September 02, 2025 – Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease – – Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial
Kraig Biocraft Laboratories' Lead Sericulture Expert Joins Recombinant Spider Silk Production Team at New Rearing Facility in Southeast Asia GlobeNewswire September 02, 2025 ANN ARBOR, Mich., Sept. 02, 2025 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that Dr. Nirmal Kumar,
Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities Veeva Systems(NYSE: VEEV) today announced more than 450 companies, including 19 of the top 20 biopharmas, have adopted Veeva RIM for regulatory information management (RIM) on a unified platform. Continued innovation to advance connectivity now includes partnerships with Accumulus Technologies and DNAnexus,